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Atherosclerosis is characterized by the retention of lipids in foam cells in the
arterial intima. The liver X receptor (LXR) agonist GW3965 is a promising
therapeutic compound, since it induces reverse cholesterol transport in foam
cells. However, hepatic LXR activation increases plasma and liver lipid levels,
inhibiting its clinical development. Herein, a formulation that specifically
enhances GW3965 deposition in the atherosclerotic lesion is aimed to be
developed. GW3965 is encapsulated in liposomes functionalized with the
cyclic peptide Lyp-1 (CGNKRTRGC), which binds the p32 receptor expressed
on foam cells. These liposomes show preferential uptake by foam cells in vitro
and higher accumulation in atherosclerotic plaques in mice compared to
non-targeted liposomes as determined by in vivo imaging. Flow cytometry
analysis of plaques reveals increased retention of Lyp-1 liposomes in
atherosclerotic plaque macrophages compared to controls (p < 0.05). Long
term treatment of established plaques in LDLR -/- mice with
GW3965-containing Lyp-1 liposomes significantly reduces plaque macrophage
content by 50% (p < 0.01). Importantly, GW3965-containing Lyp-1 liposomes
do not increase plasma or hepatic lipid content. Thus, GW3965-containing
Lyp-1 liposomes successfully target the atherosclerotic macrophages allowing
plaque stabilization without commonly observed side effects of LXR agonists.
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Atherosclerosis is the predominant under-
lying pathology of cardiovascular disease
and is one of the leading causes of death
worldwide.[1] It is characterized by chronic
inflammation in medium-and large-sized
arteries caused by the subendothelial accu-
mulation of oxidized low-density lipopro-
tein (oxLDL).[2] This attracts immune cells,
such as monocytes, which upon differen-
tiation into macrophages clear oxLDL via
scavenger receptors and can transform into
large lipid-laden foam cells.[3] These foam
cells are unable to migrate out of the
vessel wall, leading to a build-up at the
site of inflammation and the formation of
atherosclerotic plaques.[4]
There is increasing evidence that the
migratory capacity of foam cells out of
atherosclerotic plaques can be restored after
cholesterol efflux.[5] Therefore, a promising
treatment strategy to reverse the formation
of foam cells is to stimulate this process.[6]
Lipid-laden macrophages can actively
transport excess cholesterol across their
membrane via the ATP-binding cassette (ABC) transporters
ABCA1 and ABCG1.[7] The liver X receptor (LXR) is a member of
a family of nuclear transcription factors (LXR𝛼; LXR𝛽) involved
in the regulation of lipid homeostasis in response to altered sterol
levels and controls the expression of both ABC transporters.[7]
The deletion of these transcription factors in mice is associated
with a remarkable increase in atherosclerotic lesions,[8] imply-
ing therapeutic value of modulating LXR activity in atheroscle-
rosis. A class of small molecules, called LXR agonists (e.g.,
GW3965[9]), can activate this receptor to subsequently increase
the efflux of excess cholesterol from foam cells via the induction
of ABCA1 and ABCG1, reducing the local lipid content and en-
abling subsequent clearance of these cells from the plaque.[10]
Several studies have demonstrated the beneficial effects of LXR
agonists on reducing atherosclerotic plaque burden;[11] how-
ever, LXR expression is not restricted to macrophages. LXR𝛼 is
abundantly present in the liver, intestine, adipose tissue, spleen,
and kidney[12] and LXR𝛽 is ubiquitously expressed, although at
a lower level. Therefore, when administered systemically, LXR
agonists may affect several organs.[12] Activation of LXR𝛼 in the
liver leads to high triglyceride levels in the plasma and liver.[13,14]
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Figure 1. Synthesis of DSPE-PEG2000-Lyp-1. Schematic representation of the reaction coupling DSPE-PEG2000-COOH to cyclic peptide Lyp-1 to produce
DSPE-PEG2000-Lyp-1.
Table 1. Physicochemical properties of liposomal formulations.
Formulation Z-average diameter ± SD [nm] PDI ± SD 𝜁 -potential ± SD [mV] Encapsulation efficiency ± SD [%]
Empty Lyp-1 liposomes 84.7 ± 3.9 0.09 ± 0.02 −19.3 ± 2.3 —
GW3965-loaded liposomes 73.8 ± 4.9* 0.10 ± 0.02 −19.7 ± 2.3 93.5 ± 19.9
GW3965-loaded Lyp-1 liposomes 77.5 ± 4.0* 0.09 ± 0.02 −19.5 ± 2.1 92.9 ± 22.5
Average particle diameter (Z-average diameter), PDI, and 𝜁 -potential were determined for all liposomal formulations. Encapsulation efficiency was calculated for liposomes
loaded with GW3965 compound. *p < 0.05 compared to empty Lyp-1 liposomes.
This unwanted effect of LXR agonism could be prevented by
altering the biodistribution of the active compound, directing
it away from the liver and increasing the effective dose at the
target site; the atherosclerotic lesion. Encapsulation of active
compounds in a drug delivery vehicle such as a nanoparticle
is an effective strategy to alter their biodistribution.[15] In addi-
tion, conjugation of a targeting molecule to the drug delivery
vehicle will direct the active compound to the required site of
action.[16] Targeting to atherosclerotic plaques generally focuses
on targeting to endothelial cells,[17–19] clotted plasma proteins,[20]
or macrophages,[21,22] by using HDL-like nanoparticles,[23] or by
passive targeting via sheer stress-mediated extravasation.[24] A
common problem with many targeting strategies is lack of pen-
etration into the plaque[19,20] or non-specificity.[22,24] The cyclic
peptide Lyp-1 (CGNKRTRGC) has been identified as a valu-
able tool with a remarkable ability to penetrate into atheroscle-
rotic plaques, making it superior for targeting macrophages in
atherosclerotic plaques than other targeting peptides.[25] It binds
to p32, also known as gC1q receptor, a receptor for the globular
head domains of the complement component C1q. This receptor
was originally found to be overexpressed on the cell surface of
tumor cells[26] but is also expressed on foam cells in atheroscle-
rotic plaques.[27] Nanoparticles coupled to Lyp-1 have been used
for imaging of atherosclerotic plaques,[28,29] but so far, no stud-
ies have been performed using Lyp-1-targeted nanoparticles as
treatment against atherosclerosis.[30]
In this study, we aimed to design a particulate formulation
combining the targeting properties of Lyp-1 with the therapeu-
tic effect of an LXR agonist (GW3965) to promote cholesterol
efflux from foam cells in atherosclerotic plaques to slow down
atherosclerotic plaque development or reverse disease. We hy-
pothesized that delivery of GW3965 with targeted liposomes will
increase the retention of loaded particles in the atherosclerotic
plaque, thereby reducing foam cell content in the plaque.
2. Results
2.1. Characterization of Lyp-1 Starting Materials and Liposomes
The coupling reaction of cyclic Lyp-1 to 1,2-distearoyl-sn-glycero-
3-phosphoethanolamine-N-[carboxy(polyethylene glycol)-2000]
(DSPE-PEG2000-COOH) generating DSPE-PEG2000-Lyp-1 is
schematically represented in Figure 1 and was confirmed by
MALDI-MS (Figure S1, Supporting Information). All GW3965-
loaded liposomes showed an encapsulation efficiency of this drug
of nearly 100% (Table 1). The Z-average diameter of GW3965-
loaded liposomes (≈75 nm) was slightly, but significantly (p
< 0.05) smaller than that of empty liposomes (≈85 nm) (Table 1).
The polydispersity index (PDI) was ≈0.1 for all formulations,
and the 𝜁 -potential was about −20 mV (Table 1).
2.2. Lyp-1 Liposomes Preferentially Associate with Foam Cells In
Vitro
To test the specific association of the liposomes to foam cells
in vitro, fluorescently labeled liposomes were incubated with
LDLr−/− mouse-derived non-differentiated bone marrow-derived
macrophages (BMMs) (M0) and oxLDL-laden foam cells for
2 h. Flow cytometric analysis showed that both non-targeted
and targeted liposomes did not associate with M0 macrophages
(Figure 2). Consistent with previous reports,[19] foam cells
showed enhanced association with both targeted and
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Figure 2. Preferential association of targeted Lyp-1 liposomes to foam cells in vitro. LDLr−/− M0 macrophages and oxLDL-laden foam cells were exposed
to non-targeted liposomes or Lyp-1 liposomes labeled with DOPC-Cy5. After 2 h of incubation, the liposomal association was determined by using flow
cytometry. A) Representative MFI plots. Cell association was expressed as B) mean fluorescence intensity of the cells and C) percentage of cells positive
for the fluorescent label. Graphs show means + SD of three independent experiments, *p < 0.05 comparing foam cells to M0 macrophages, #p < 0.05
comparing non-targeted to targeted liposomes, determined by two-way ANOVA and Bonferroni’s post-test.
non-targeted liposomes. However, the interaction of Lyp-1
targeted liposomes was significantly increased as compared
to non-targeted liposomes, marked by a higher fluorescent
signal (Figure 2A,B) and a nearly fourfold increase in the per-
centage of liposome positive foam cells (p < 0.05) (Figure 2C).
Similar results (fourfold increase, p < 0.01) were observed for
M0 macrophages and foam cells both derived from wild-type
(WT) mice containing a functional LDL receptor (data not
shown).
2.3. Lyp-1 Liposomes Are Retained in Plaque-Residing Foam Cells
of LDLr−/− Mice
Next, we addressed the ability of the Lyp-1 liposomes to accu-
mulate in foam cells residing in atherosclerotic plaques in vivo.
LDLr−/− mice fed a Western-type diet (WTD) for 13 weeks were
injected intravenously with fluorescently labeled Lyp-1 liposomes
or non-targeted liposomes. After 3 h, mice were anesthetized
and perfused, and the biodistribution of liposomes was assessed
using fluorescence imaging (see Figure 3A 3,B for representative
aortas) and flow cytometry (see Figure 3C,D for representative
plots). Lyp-1 liposomes showed a significantly higher accumu-
lation in atherosclerotic plaques compared to non-targeted lipo-
somes, as shown by the total radiant efficiency (29-fold increase,
p < 0.01, Figure 3E) and the relative fluorescence signal (25-
fold increase, p < 0.001, Figure 3F). Flow cytometric analysis
confirmed a 1.7-fold (p < 0.05) increase in the accumulation
of Lyp-1 targeted liposomes in atherosclerotic plaque foam
cells as compared to non-targeted control liposomes (Fig-
ure 3G). In addition, to determine the organ distribution of
the liposomes, the liver, kidneys, heart, spleen, and lungs
were collected and separately imaged with in vivo imaging
system (IVIS). Most liposomes (both targeted and non-targeted)
accumulated in the spleen, liver, and kidneys, and a small
amount was recovered from the lungs and hearts (Figure S2,
Supporting Information). LDLr−/− mice that received chow diet
instead of WTD, and therefore did not develop atherosclerotic
plaques, did not show any liposomal signal in aortas (data not
shown).
2.4. Treatment with GW3965-Loaded Lyp-1 Liposomes
Significantly Reduces the Macrophage Content and Increases the
Collagen Content of Atherosclerotic Plaques
After confirming efficient targeting of the Lyp-1 liposomes to
atherosclerotic foam cells, the effect of Lyp-1 liposomal targeting
of the LXR agonist GW3965 on pre-established atherosclerotic
lesions was assessed. Male LDLr−/− mice were fed WTD for
8 weeks. At this point, the average plaque size in the aortic
root area was ≈0.12 ± 0.07 mm2, with lesion area comprising
57.1 ± 15.2% macrophages, and 1.3 ± 1.1% collagen. Subse-
quently, the mice were injected intravenously twice a week with
phosphate buffered saline (PBS), free GW3965, empty Lyp-1
liposomes, GW3965-loaded liposomes or GW3965-loaded Lyp-1
liposomes for 5 weeks, during which the WTD was maintained.
Upon sacrifice, no differences were observed in atheroscle-
rotic plaque size between any of the groups as determined in
Oil Red O stained sections of the aortic roots (Figure 4A,D).
However, the macrophage content, as measured with MOMA2
staining, was twofold (p < 0.05) lower in mice treated with
Lyp-1 targeted GW3965-loaded liposomes compared to all other
groups (Figure 4B,E). Previous studies have shown a positive
correlation between the reduction in macrophage content
and increase in collagen content in the plaque.[31] Indeed, we
found that the percentage of collagen in the plaques was sig-
nificantly increased (threefold, p < 0.01) in mice treated with
GW3965-loaded Lyp-1 liposomes as compared to all other groups
(Figure 4C,F). Thus, foam cell delivery of GW3965 using Lyp-1
liposomes induced stabilization of established atherosclerotic
plaques.
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Figure 3. Association of fluorescently labeled non-targeted liposomes and Lyp-1 liposomes by plaque-residing foam cells in LDLr−/− mice fed WTD for
13 weeks. 3 h after intravenous injection of liposomes, mice were perfused with PBS (pH 7.4 at RT). Representative IVIS images of descending aortas of
mice that had received A) non-targeted and B) Lyp-1 liposomes. The dark brown signal indicates the presence of the Cy5 label. Representative FACS plots
of pre-gated CD45+MHC-II+F4/80+ cells isolated from the aortic arch associated with C) non-targeted and D) Lyp-1 liposomes. E) Radiant efficiency
of the fluorescent label in the descending aortas of mice measured by fluorescence imaging, n = 5. F) Aortic radiant efficiency as a percentage of all
organs, n = 5. G) Liposomes detected in CD45+MHC-II+F4/80+ cells isolated from the aortic arch by flow cytometry, n = 8. Graphs show mean + SD;
*p < 0.05, **p < 0.01, ***p < 0.001 determined by unpaired t-test.
2.5. Free or Encapsulated GW3965 Does Not Affect Plasma and
Liver Lipid Content
Despite the positive effects of LXR activation on atherosclerosis,
the use of LXR agonists, such as GW3965, has been described
to alter hepatic lipid metabolism often leading to an increase in
circulating triglycerides and liver steatosis.[10] Triglyceride and
cholesterol content (in both plasma and liver) showed no dif-
ferences between any of the groups (Figure 5), suggesting that
the GW3965 treatment with Lyp1 targeted liposomes can stabi-
lize atherosclerotic plaques without the confounding effects on
serum and liver lipid levels.
3. Discussion
LXR agonists are promising compounds for the treatment of
atherosclerosis, but at therapeutic doses, they increase plasma
triglyceride and cholesterol levels.[13,14] In this study, we showed
that loading of an LXR agonist, GW3965, in Lyp-1-bearing lipo-
somes induces a highly relevant stabilization of pre-established
atherosclerotic lesions, in contrast to free GW3965 or GW3965
encapsulated in non-targeted liposomes. This is hypothesized
to be due to the migration of macrophages out of lesions af-
ter LXR-agonist-induced cholesterol efflux.[5] Liposomes consist-
ing of DOPC:DOPS:DSPE-PEG:DSPE-PEG-Lyp-1 in a molar ra-
tio of 76:19:4.3:0.7 were prepared to produce particles with fluid
state membranes to improve the encapsulation of GW3965 and
to prevent mononuclear phagocyte uptake upon injection into
the circulation. Phosphatidylserine was added because of its anti-
inflammatory properties[32] and reported ability to target foam
cells.[22] Liposomes were PEGylated (5 mol%) to enhance their
circulation time.[33]
To minimize the undesired hepatic and metabolic effects,
LXR agonists can be encapsulated into functionalized nanopar-
ticles to target atherosclerotic plaques. Zhang et al. formulated
GW3965 in PEGylated PLGA nanoparticles containing phos-
phatidylserine on the surface to target atherosclerotic foam
cells. The targeted PLGA particles (10 mg/kg GW3965; ad-
ministered iv three times per week for 2 weeks) reduced the
macrophage content in the lesion compared to untreated con-
trol. However, this effect was not enhanced when compared
to free drug or drug encapsulated in non-targeted liposomes
and was accompanied by increased hepatic and plasma triglyc-
eride and cholesterol levels.[22] In a different approach, Yu et al.
encapsulated GW3965 in methoxy-PLA nanoparticles coated
with 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC):DSPE-
PEG1000 functionalized with collagen-IV-targeting heptapeptide
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Figure 4. Effect of GW3965-loaded Lyp-1 targeted liposomes on plaque development in LDLr−/− mice. Mice were fed WTD for 8 weeks before receiving
intravenous injections of GW2965-loaded Lyp-1 liposomes or controls twice a week for 5 weeks while maintaining WTD. Upon sacrifice, hearts were
collected and sectioned to reveal the aortic root area. Sections were stained for A) Oil Red O to visualize lipids B) MOMA2 to measure macrophage
content, and C) Sirius Red for collagen content, n = 10. Representative images of section stained for D) Oil Red O, E) MOMA2, and F) Sirius Red. Graphs
show means + SD; *p < 0.05, **p < 0.01, ***p < 0.001 determined by one-way ANOVA with Holm–Sidak post-test.
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Figure 5. Effect of drug-loaded targeted liposomes and controls on lipid levels in plasma and liver of LDLr−/- mice on WTD. Mice received WTD for
8 weeks before receiving intravenous injections of liposomes or controls twice a week for 5 weeks while maintaining WTD. Mice received the last injection
3 h prior to sacrifice. Upon sacrifice, plasma and livers were collected for lipid analysis. A) Total cholesterol and B) triglyceride levels were measured
in plasma. Livers were processed and total protein content in mg was determined. C) Total cholesterol and D) triglyceride levels were measured and
normalized to protein content. E) Representative image of Oil Red O stained liver of a mouse that received PBS, or (F) drug-loaded targeted liposomes,
n = 10. Graphs show mean + SD; no significant differences found between groups were determined by one-way ANOVA with Holm–Sidak post-test.
conjugated to DSPE-PEG2000 in the lipid layer. The GW3965-
loaded collagen-targeting particles (8 mg/kg, administered in-
travenously two times per week for 5 weeks) significantly de-
creased the CD68+ (macrophage) area in the lesion compared to
free drug and non-targeted liposomes.[17] Neither of these pre-
viously described targeting approaches using collagen-IV and
phosphatidylserine resulted in a reduction in total plaque size.
Furthermore, the collagen content in the plaques, an important
indicator of plaque stability, was not measured in these studies.
It should be noted that, while in humans foam cells are mainly
derived from macrophages,[34] it has recently been discovered
that foam cells can be derived from smooth muscle cells in the
ApoE−/− mouse model.[35] Since the aforementioned studies and
the study presented here are performed in LDLr−/− mice, it is
unknown whether the therapeutic effect would be the same in
ApoE−/− mice.
In this study, we made use of the interaction between the p32
receptor and Lyp-1 to target liposomes to foam cells in the plaque
and deliver GW3965. Since the p32 receptor is not expressed on
the surface of lipid-poor macrophages,[26] the presence of Lyp-1
on the liposomal surface did not affect the in vitro association of
the liposomes to undifferentiated macrophages but greatly and
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significantly enhanced their association to foam cells, confirm-
ing the selectivity of the targeting peptide. It should be noted that
p32 has been found to be expressed in endothelial cells, foam
cells, smooth muscle cells, and inflammatory cells present in the
intima and media of human atherosclerotic lesions.[27] However,
similar to the Lyp-1 liposomes described here, heat shock protein
cages functionalized with Lyp-1 designed by Uchida et al. showed
accumulation in Mac-3+ foam cells in murine ligation-induced
atherosclerotic plaques.[28] Seo et al. also observed high aortic le-
sion retention of Lyp-1 dendrimers 3 h after intravenous injec-
tion in ApoE−/− mice.[29] Remarkably, in our study, the presence
of Lyp-1 on the liposomal surface leads to enough particle reten-
tion in the aorta to allow a clear therapeutic effect of a relatively
low dose of GW3965 (≈6.5 mg/kg/injection). For reference, the
administration of a high dose of free GW3965 (10 mg/kg) orally
for 12 weeks significantly reduced lesion size, but this effect was
accompanied by higher serum triglycerides levels.[14]
Administration of free or nanoparticle-encapsulated LXR ago-
nist may not fully prevent unwanted effects in the plasma and in
the liver.[10] In the present study, the high hepatic uptake of our
GW3965-loaded Lyp-1 liposomes did not lead to the side effects
typically associated with LXR agonists. Joseph et al. showed that
treatment with free GW3965 at a low dose (1 mg/kg for 12 weeks)
did not result in plaque size reduction, hypertriglyceridemia or
liver steatosis. The administration of a moderate dose of GW3965
(6.5 mg/kg in this study, vs 10 mg/kg by Zhang et al.[22] and
8 mg/kg by Yu et al.[17]) may have contributed to maintenance
of hepatic and serum lipid homeostasis, as free GW3965 also did
not induce these unwanted effects. The aforementioned studies
along with our own study demonstrate that uptake of nanoparti-
cles by cells in the liver is difficult to avoid, especially by Kupffer
cells,[36] but nanoparticles can still protect against the unwanted
effects of the LXR agonist while increasing the efficiency of the
drug at the site of action. Nevertheless, high hepatic particle up-
take in the long-term, especially with higher doses should be
avoided. Thus, other liposomal formulations or even other types
of particles could be explored to reduce the undesired particle re-
moval by the liver.
In conclusion, our work shows that functionalizing liposomes
with Lyp-1 is an excellent strategy for targeting to atherosclerotic
plaques. We are, to our knowledge, the first to combine this tar-
geting approach with an LXR agonist, and we show that GW3965
loaded in targeted liposomes can reduce plaque macrophage
content and increase plaque stability. These findings suggest that
it is possible to increase the efficacy of this LXR agonist and may
contribute to the development of better atherosclerosis therapies.
4. Experimental Section
Materials and Chemicals: Rat and mouse no. 3 breeding chow
diet and WTD containing 0.25% cholesterol and 15% cocoa butter
were purchased from Special Diet Services, Essex, UK. 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC), DOPC-cyanine 5 (DOPC-Cy5),
1,2-dioleoyl-sn-glycero-3-phospho-l-serine (DOPS), DSPE-PEG2000,
and DSPE-PEG2000-COOH were purchased from Avanti Polar Lipids
(Alabaster, AL, USA). using O-(1H-6-chlorobenzotriazole-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HCTU) and all amino acids
used for synthesis were obtained from Novabiochem (Amsterdam, the
Netherlands). N-N′-diisopropylethylamine (DIPEA) and Oxyma were
purchased from Carl Roth (Karlsruhe, Germany). Dichloromethane
(DCM) was obtained from Honeywell (Amsterdam, the Netherlands).
Roswell Park Memorial Institute Medium (RPMI 1640), l-glutamine, and
penicillin/streptomycin were purchased from Lonza (Basel, Switzerland).
Fetal calf serum (FCS) was bought from PAA Laboratories (Ontario,
Canada) and polycarbonate track-etched pore size membranes (400,
200, and 50 nm pore size) were obtained from Whatman Nucleopore,
GE Healthcare (Little Chalfont, UK). 70-µm cell strainer and 96-well
plates were purchased from Greiner Bio-One B.V. (Alphen aan den
Rijn, the Netherlands). Monosodium phosphate (NaH2PO4), disodium
phosphate (Na2HPO4), diethyl ether, triisopropylsilane, iodine, di-
isopropylcarbodiimide, GW3965, Oil Red O, Sirius Red, hematoxylin,
Nonidet P 40 Substitute, chloroform, collagenase I, collagenase XI,
DNase, and hyaluronidase were purchased from Sigma-Aldrich (Zwijn-
drecht, The Netherlands). Dulbecco’s Modified Eagle Medium (DMEM)
low glucose, non-essential amino acids, pyruvate, oxidized LDL, Pierce
BCA Protein Assay Kit, were purchased from ThermoFisher (MA, USA).
Sodium chloride (NaCl) was obtained from Boom (Meppel, The Nether-
lands). Trifluoroacetic acid (TFA), piperidine, dimethylformamide (DMF),
potassium dihydrogen phosphate (KH2PO4), potassium chloride (KCl),
methanol and acetonitrile were purchased from Biosolve (Valkenswaard,
the Netherlands). Optimal cutting temperature formulation Tissue-Tek
O.C.T. was purchased from Sakura Finetek (Alphen aan den Rijn, The
Netherlands). Cholesterol and triglycerides colorimetric assays were
obtained from Roche Diagnostics (Almere, The Netherlands). Rat anti-
mouse macrophages/monocytes antibody (MOMA2) was purchased
from Bio-Rad (Veenendaal, the Netherlands). Ketamine and atropine
were purchased from AUV Veterinary Services (Cuijk, the Netherlands)
and xylazine from ASTFarma (Oudewater, the Netherlands). CD45-
AlexaFluor700 (30-F11) was obtained from Biolegend (San Diego, CA,
USA). F4/80-FITC (BM8), fixable viability dye eFluor780, and MHC-II-
eFluor450 (AF6-120.1) were purchased from eBioscience (San Diego, CA,
USA). All solvents used were of analytical grade.
Animals: WT and LDL receptor knockout (LDLr−/−) mice on a
C57BL/6 background were purchased from Jackson Laboratory (CA, USA),
bred in-house under standard laboratory conditions, and provided with
food and water ad libitum. Information about the diet used for individ-
ual experiments is described in each section. The regular laboratory diet
(chow) was rat and mouse no. 3 breeding diet. WTD contained 0.25 wt%
cholesterol and 15 wt% cocoa butter. Animals had access to water and
food ad libitum. All animal work was performed in compliance with the
Dutch government guidelines and the Directive 2010/63/EU of the Euro-
pean Parliament. Experiments were approved by the Ethics Committee for
Animal Experiments of Leiden University.
DSPE-PEG2000-Lyp-1 Synthesis: The Lyp-1 peptide, GCGNKRTRGC
with Cys residues protected by the non-acid-labile acetamidomethyl group,
was synthesized using a Liberty Blue microwave-assisted peptide syn-
thesizer. The synthesis was performed on a 0.1 mmol scale with a low-
loading (0.18 mmol g−1) tentagel R-RAM resin. Amino acid activation
was achieved by using N,N′-diisopropylcarbodiimide as the activator and
Oxyma as the base, while Fmoc-deprotection was achieved with 20%
piperidine in DMF. Once the synthesis was complete, the resin was treated
with 10 equivalents of iodine for 1 h, to accommodate the concomitant
deprotection and cyclization of the Cys residues. The resin was subse-
quently washed five times with DMF, five times with 2% acetic acid in
DMF, five times with DMF and finally five times with DCM. The DSPE-
PEG2000-COOH was manually coupled, on resin, to the N-terminus of an
excess of the cyclized Lyp-1 by HCTU and DIPEA. The coupling reaction
was left overnight, and the resin was subsequently washed with DMF and
DCM. The DSPE-PEG2000-Lyp1 was cleaved from the resin by using a mix-
ture of 97% TFA and 3% triisopropylsilane. The cleavage reaction was left
to proceed for 1 h, and the peptide was precipitated into ice-cold diethyl
ether. The precipitate was collected by centrifugation. Levels of precipitate
were low, likely due to the hydrophobic nature of the lipopeptide, there-
fore after centrifugation, the ether was separated from the precipitate and
the ether was evaporated, leaving a white residue. This residue was com-
bined with the original precipitate, dissolved in a mixture of acetonitrile
and water, and dialyzed in a solution of 90% water and 10% acetonitrile
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to remove the excess uncoupled peptide and any scavengers or impurities
that remained. The product was subsequently freeze-dried and analyzed
using MALDI mass spectrometry to confirm the desired product had been
formed.
Liposome Preparation: Liposomes were prepared by using the thin
film dehydration-rehydration method, as described previously.[37] Briefly,
DOPC:DOPS:DSPE-PEG:DSPE-PEG-Lyp-1 in the molar ratio 76:19:4.3:0.7
were dissolved in chloroform and mixed in a round-bottom flask to obtain
a final lipid concentration of 10 mg mL−1. To this mixture, 2 mg of GW3965
was added. Chloroform was evaporated for 1 h at 40 °C in a rotary evapo-
rator (Rotavapor R-210, Büchi, Switzerland). The lipid film was rehydrated
with 1 mL Milli-Q water and homogenized by using glass beads and gentle
swirling at room temperature (RT). The liposome dispersion was subse-
quently snap-frozen in liquid nitrogen, followed by freeze-drying overnight
(Christ alpha 1–2 freeze-dryer, Osterode, Germany). The resulting dry lipid
cake was gradually rehydrated at RT by using 10 mm phosphate buffer
(PB), pH 7.4; two volumes of 500 µL and one volume of 1000 µL PB were
successively added, with intervals of 30 min between each addition. The
mixture was vortexed well between each hydration step, and the resulting
dispersion was kept at RT for at least 1 h. To obtain monodisperse lipo-
somes, the multilamellar vesicles were sized by high-pressure extrusion at
RT (LIPEX Extruder, Northern Lipids Inc., Canada). The liposome mixture
was passed four times through stacked 400 and 200 nm polycarbonate
track-etched pore size membranes and a further eight times through a
50 nm pore size membrane. To prepare fluorescently labeled liposomes,
0.1 mol% of DOPC was replaced with DOPC-Cy5. Liposomes were stored
at 4 °C and used for further experiments within 1 week.
Liposome Characterization: The Z-average diameter and PDI of the li-
posomes were measured by dynamic light scattering using a NanoZS Ze-
tasizer (Malvern Ltd., Malvern, UK). Zeta-potential of the liposomes was
determined by laser Doppler electrophoresis with the same instrument.
Liposomes were diluted 100-fold in PB to a total volume of 1 mL prior to
measuring. To determine the concentration of encapsulated GW3965 and
Lyp-1, samples were analyzed by reversed-phase UPLC (Waters ACQUITY
UPLC, Waters, MA, USA). 20 µL of the liposome dispersion was dissolved
in 180 µL methanol. 10 µL of the sample was injected into a 1.7 µm BEH
C18 column (2.1 × 50 mm, Waters ACQUITY UPLC, Waters, MA, USA).
The column temperature and the temperature of the sample were set at
40 and 4 °C, respectively. The mobile phases were Milli-Q water with 0.1%
TFA (solvent A) and acetonitrile with 0.1% TFA (solvent B). For detection,
the mobile phases were applied in a linear gradient from 5% to 95% sol-
vent B over 10.5 minutes at a flow rate of 0.370 mL min−1. Lyp-1 was de-
tected by absorbance at 220 nm using an ACQUITY UPLC TUV detector
(Waters ACQUITY UPLC, Waters, MA, USA) and GW3965 was detected at
272 nm.
BMM and Foam Cell Culture: Bone marrow was isolated from the
tibias and femurs of WT or LDLr−/− mice on a chow diet. The isolated
bone marrow was passed through a 70-µm cell strainer. To differentiate
the bone-marrow derived cells into macrophages, the cells were cultured
in mixture of 60% complete RPMI medium (20% (v/v) FCS, 2 mm l-
glutamine, 1 mm non-essential amino acids, 1 mm pyruvate, and 100 U
mL−1 penicillin/streptavidin with 40% complete L929-conditioned DMEM
low glucose medium (10% (v/v) FCS, 2 mm l-glutamine, and 100 U mL−1
penicillin/streptavidin) at 37 °C and 5% CO2 for 7 days, as described
previously.[38] The medium was refreshed every other day. To generate
foam cells, macrophages were incubated with 75 µg mL−1 oxLDL for 30 h.
Liposome Association to BMMs and Foam Cells: Bone marrow-derived
macrophages (BMMs) and foam cells were cultured as described above.
After 10 days of culture, 100 000 BMMs or foam cells were plated in 96-well
plates and fluorescently labeled Lyp-1 liposomes or controls (PBS) and flu-
orescently labeled non-targeted liposomes) were added at a concentration
of 0.35 mg mL−1 Lyp-1 or an equivalent lipid dose. After 2 h of incubation
at 37 °C and 5% CO2, excess liposomes were removed by washing the cells
several times with medium. Cells were stained for F4/80 and viability dyes
and were analyzed by flow cytometry (CytoFLEX S, Beckman Coulter, CA,
USA). Data were analyzed by using FlowJo software (Treestar, OR, USA).
In Vivo Targeting to Atherosclerotic Plaques: Male LDLr−/− mice (6 to
10-week-old) were fed WTD for 13 weeks to stimulate atherosclerotic
lesion development. Subsequently, the mice were randomized into two
groups (n = 10) injected intravenously with either Cy-5 fluorescently la-
beled non-targeting liposomes or Lyp-1 targeting liposomes (200 µL). The
Lyp-1 concentration was 35 µg for Lyp-1 liposomes, and the equivalent
lipid concentration was used for non-targeted liposomes. After 3 h, the
mice were anesthetized by using a mixture of ketamine (40 mg mL−1),
atropine (50 µg mL−1), and sedazine (6.25 mg mL−1) and perfused with
PBS (8.13 g L−1 NaCl, 2.87 g L−1 Na2HPO4, 0.2 g L
−1 KH2PO4, 0.19 g L
−1
KCl, pH 7.4) via the left ventricle of the heart under physiological pressure
after opening the thoracic cavity. After perfusion, the mice were imaged by
using a fluorescence IVIS (Perkin-Elmer IVIS Lumina Series III, Waltham,
MA, USA) to provide information about the biodistribution of the lipo-
somes. Afterward, spleen, lungs, liver, kidneys, hearts, and aortas were
also imaged separately. Uptake by different organs was plotted as radiant
efficiency and as relative radiant efficiency (%). To calculate relative radi-
ant efficiency, the total sum of signals in organs was set to 100%, and the
relative percentage per organ was calculated from this value. Aortas were
further processed for flow cytometry analysis, as previously described.[39]
Briefly, aortas were cut into small pieces, incubated with 450 U mL−1 colla-
genase I, 250 U mL−1 collagenase XI, 120 U mL−1 DNase, and 120 U mL−1
hyaluronidase (30 min at 37 °C under constant agitation), and strained
through a 70-µm cell strainer to obtain a single-cell suspension. Cells were
stained for CD45, F4/80, MHC-II, and viability and analyzed by flow cytom-
etry.
Analysis of Atherosclerosis in Mice: Male LDLr−/− mice (6 to 10-week-
old) were fed WTD for 8 weeks to develop atherosclerotic lesions. Next,
these mice were randomized into 5 groups (n = 10 mice) to receive in-
travenous injections twice a week (200 µL) of 1) PBS; 2) free GW3965;
3) empty Lyp-1 liposomes; 4) GW3965-loaded liposomes; or 5) GW3965-
loaded Lyp-1 liposomes. For GW3965-containing groups, the dose was
6.5 mg/kg GW3965. The mice were treated for 5 weeks and continued
to receive WTD during this time. After 5 weeks of treatment, the mice
were anesthetized, exsanguinated, and perfused, as described in the pre-
vious section. Hearts, livers, and blood were collected for further analysis.
Hearts were embedded in OCT and stored at −80 °C until further pro-
cessing. Cryosections of the aortic root (10 µm, CM3050S cryostat, Leica,
Rijswijk, the Netherlands) were collected. The sections were stained for
Oil Red O to visualize lipid-rich plaques.[40] The largest Oil Red O posi-
tive section of a sample and the two flanking sections were used to quan-
tify the average plaque size. Macrophage positive area in the plaque was
determined by using MOMA2 staining.[41] Macrophage positive area was
calculated as the area positive for the MOMA2 staining divided by the total
plaque area for the three largest consecutive sections. Collagen content in
the plaques was measured by using Sirius Red staining.[42] Sections were
visualized under polarized light[43] and the collagen content was deter-
mined by dividing the area positive for the Sirius Red staining by the total
plaque area for the three largest consecutive sections. All stainings were
imaged by using a Leica DM-RE microscope (Leica, Imaging Systems, UK)
and analyzed using Leica QWin software.
Lipid Quantification: Triglycerides were extracted from liver samples
(±50 mg tissue) homogenized with Nonidet P 40 Substitute. To solubilize
the triglycerides in the homogenate, the samples underwent two cycles of
heat (90 °C) and chill on ice. Subsequently, the homogenates were cen-
trifuged (14 000 rpm) to remove insoluble material and triglycerides were
measured by a colorimetric enzymatic assay.[44] The Folch method[45] was
used to extract cholesterol from liver samples (≈50 mg tissue). Choles-
terol was then quantified by using a colorimetric enzymatic assay.[44] Both
triglyceride and cholesterol levels were corrected for total protein concen-
tration. Protein concentration was determined with a Pierce BCA Protein
Assay Kit according to the manufacturer’s instructions. Non-fasted plasma
levels of cholesterol and triglycerides were measured by enzymatic colori-
metric assays, as previously described by Out et al.[44]
Statistical Analysis: Statistical analysis was performed by using Graph-
Pad Prism 8 (GraphPad Software Inc., CA, USA). Data are presented as
mean ± standard deviation (SD) and p-values below 0.05 were considered
significant. For comparison of multiple treatment groups, unpaired t-test,
one-way ANOVA with Holm–Sidak post-test, or two-way ANOVA with Bon-
ferroni’s post-test were used, where appropriate.
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